Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637111 | 0.79 | TSHR (0.38) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3639687 | 0.76 | KMT2A (0.41) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3746272 | 0.73 | MEN1 (0.46) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3743336 | 0.73 | GHSR (0.48) | — | |
| SCHEMBL3637387 | 0.73 | MEN1 (0.46) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3636978 | 0.73 | GHSR (0.48) | — | |
| SCHEMBL3743771 | 0.72 | KMT2A (0.43) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3637374 | 0.72 | KMT2A (0.43) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3637676 | 0.72 | CHRM2 (0.49) | TSHRKMT2AMEN1CHRM2CHRM1 | |
| SCHEMBL3746508 | 0.72 | CHRM2 (0.49) | TSHRKMT2AMEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | TSHR 47/4885CCR5 3138/4885ABCB1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.